PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-08-09 pm EDT
49.78 USD   +0.42%
04:24aViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox Emergency Response Fund in the US
AQ
01:21aPfizer spending spree filters to Biopharma
AQ
01:12aPfizer Managing Director Tenders Resignation
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, Inc. : The comeback of an upward trend can be anticipated

03/07/2022 | 02:34am EDT
long trade
Target price hit
Entry price : 48.25$ | Target : 53$ | Stop-loss : 45$ | Potential : 9.84%
Shares in Pfizer, Inc. reflect an interesting technical chart pattern allowing for a bet on a reversal of the medium term trend.
Investors have an opportunity to buy the stock and target the $ 53.
Pfizer, Inc. : Pfizer, Inc. : The comeback of an upward trend can be anticipated
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,83x
Yield 2022 3,25%
Capitalization 279 B 279 B -
EV / Sales 2022 2,63x
EV / Sales 2023 3,34x
Nbr of Employees 79 000
Free-Float 58,9%
Upcoming event on PFIZER, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,78 $
Average target price 56,53 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.05%279 310
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976
NOVO NORDISK A/S4.27%238 658